Back to search results

Understanding the Long-term Impact of COVID-19 in Adults

This observational study, called RECOVER-Adult Cycle 2, aims to understand the long-term effects of Long COVID (LC) in adults. Researchers will follow over 5,000 participants for two years to learn more about how LC changes over time, what causes it, and new health problems that might develop. The study focuses on conditions affecting the brain and thinking (neurocognitive), heart and lungs (cardiopulmonary), and other chronic conditions like Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). You might be able to join if you are an adult aged 18 to 100 years and meet specific criteria for Long COVID symptoms and their impact on your quality of life. The study will measure how many participants have a high Long COVID Research Index (LCRI) score, how many experience LC remission, and how many develop new health conditions over time.

Study design
This is an observational study, meaning researchers will watch and collect information from over 5,000 participants. It is not a study testing a specific treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 24 months after joining the study, with measurements taken at 6, 12, 18, and 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07498504

Understanding the Long-term Impact of COVID-19 in Adults

Not Yet Recruiting
Not specifiedAges 18+Observational
NYU Langone Health
~5,205 participants
Updated 2026-03-27 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Long COVID Research Index (LCRI) Score of 11 or Higher
Measured over Baseline, Month 6, Month 12, Month 18, Month 24
+2 more outcomes measured

Conditions

Long COVID
Long Covid19

Explore related trials

Post-Acute Sequelae of COVID-19

NCT07498504

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • NYU Langone Health

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Leora Horwitz, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Leora Horwitz, MD
[email protected]
646-501-2685
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

RECOVER-Adult 2024 LCRI 11 or greater, as defined by Geng et al, 2024;1 or
At least 1 RECOVER-Adult LCRI symptom and either a) poor quality of life (QoL) as defined by a response of "poor" on the PROMIS-10 QoL question or b) "bother scale" is "quite a bit" or "very much" for corresponding LCRI symptom; or
At least 1 National Academies of Sciences, Engineering, and Medicine (NASEM) common symptom and either a) poor QoL, or b) "bother scale" is "quite a bit" or "very much" for corresponding NASEM symptom.

Exclusion

Individuals who have a known or documented hemoglobin lower than 8.5 g/dL,
Individuals who have not yet reached the age of majority,
Individuals who are unable to provide consent,
Individuals who are unwilling to consent to biospecimen collection or are unwilling to participate in the complete protocol, including all assessments and the cycle 2 visit schedule. Note that there are no exclusions related to blood volume collection. For healthy adults, the volume of blood collected (70.9 mL per visit and per year) is substantially lower than the federal minimal risk limit of 550 mL within 8 weeks,
Individuals in hospice care,
Individuals with a serious medical condition which would prevent in-person participation,
Individuals participating in the study NIH RECOVER-Pediatric: Understanding the long-term impact of COVID on children and families, unless enrolled only as caregiver, or
Long-term incarcerated individuals

What this trial measures

  • Percentage of Long COVID Research Index (LCRI) Score of 11 or HigherBaseline, Month 6, Month 12, Month 18, Month 24

    The LCRI 11 assesses symptoms such as malaise, brain fog, and fatigue to classify individuals into likely LC, possible LC, or no LC. A score of 11 or greater indicates high-symptom cases of LC.

  • Percentage of Participants with LC RemissionMonth 6, Month 12, Month 18, Month 24

    Percentage of participants who experience remission from LC.

  • Percentage of Participants with New Onset ConditionsMonth 6, Month 12, Month 18, Month 24

    New onset conditions include, but are not limited to, dementia, coronary artery disease, diabetes, renal disease, cancer, and myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).